{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:22:39Z","timestamp":1789687359959,"version":"4.0.1"},"reference-count":132,"publisher":"National Institute for Health and Care Research","issue":"78","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["07\/36\/01"],"award-info":[{"award-number":["07\/36\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n \n Bevacizumab (Avastin\n \u00ae<\/jats:sup>\n , Roche), which is used in cancer therapy, is the \u2018parent\u2019 molecule from which ranibizumab (Lucentis\n \u00ae<\/jats:sup>\n , Novartis) was derived for the treatment of neovascular age-related macular degeneration (nAMD). There were reports in the literature on the effectiveness of bevacizumab in treating nAMD, but no trials. The cost per dose of bevacizumab is about 5\u201310% that of ranibizumab. This trial was a head-to-head comparison of these two drugs.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the clinical effectiveness and cost-effectiveness of ranibizumab and bevacizumab, and two treatment regimens, for nAMD.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n Multicentre, factorial randomised controlled trial with within-trial cost\u2013utility and cost-minimisation analyses from the perspective of the UK NHS. Participants, health professionals and researchers were masked to allocation of drug but not regimen. Computer-generated random allocations to combinations of ranibizumab or bevacizumab, and continuous or discontinuous regimen, were stratified by centre, blocked and concealed.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n Twenty-three ophthalmology departments in NHS hospitals.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n Patients \u2265\u200950 years old with active nAMD in the study eye with best corrected distance visual acuity (BCVA) \u2265\u200925 letters measured on a Early Treatment of Diabetic Retinopathy Study (ETDRS) chart. Previous treatment for nAMD, long-standing disease, lesion diameter >\u20096000\u2009\u00b5m, thick blood at the fovea and any other confounding ocular disease were exclusion criteria. One eye per participant was studied; the fellow eye was treated according to usual care, if required.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Ranibizumab and bevacizumab were procured commercially. Doses were ranibizumab 0.5\u2009mg or bevacizumab 1.25\u2009mg. The repackaged bevacizumab was quality assured. All participants were treated at visits 0, 1 and 2. Participants randomised to the continuous regimen were treated monthly thereafter. Participants randomised to the discontinuous regimen were not retreated after visit 2 unless pre-specified criteria for active disease were met. If retreatment was needed, monthly injections over 3 months were mandated.<\/jats:p>\n <\/jats:sec>\n \n Main outcome measures<\/jats:title>\n The primary outcome was BCVA. The non-inferiority margin was 3.5 letters. Secondary outcomes were contrast sensitivity; near visual acuity; reading index; neovascular lesion morphology; generic and disease-specific patient-reported outcomes, including macular disease-specific quality of life; survival free from treatment failure; resource use; quality-adjusted life-years (QALYs); and development of new geographic atrophy (GA) (outcome added during the trial). Results are reported for the study eye, except for patient-reported outcomes.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Between 27 March 2008 and 15 October 2010, 610 participants were allocated and treated (314 ranibizumab, 296 bevacizumab; at 3 months, 305 continuous, 300 discontinuous). After 2 years, bevacizumab was neither non-inferior nor inferior to ranibizumab [\u20131.37 letters, 95% confidence interval (CI) \u20133.75 to +1.01 letters] and discontinuous treatment was neither non-inferior nor inferior to continuous treatment (\u20131.63 letters, 95% CI \u20134.01 to +0.75 letters). Lesion thickness at the fovea was similar by drug [geometric mean ratio (GMR) 0.96, 95% CI 0.90 to 1.03;\n p<\/jats:italic>\n \u2009=\u20090.24] but 9% less with continuous treatment (GMR 0.91, 95% CI 0.85 to 0.97;\n p<\/jats:italic>\n \u2009=\u20090.004). Odds of developing new GA during the trial were similar by drug [odds ratio (OR) 0.87, 95% CI 0.61 to 1.25;\n p<\/jats:italic>\n \u2009=\u20090.46] but significantly higher with continuous treatment (OR 1.47, 95% CI 1.03 to 2.11;\n p<\/jats:italic>\n \u2009=\u20090.033). Safety outcomes did not differ by drug but mortality was lower with continuous treatment (OR 0.47, 95% CI 0.22 to 1.03;\n p<\/jats:italic>\n \u2009=\u20090.05). Continuous ranibizumab cost \u00a33.5M per QALY compared with continuous bevacizumab; continuous bevacizumab cost \u00a330,220 per QALY compared with discontinuous bevacizumab. These results were robust in sensitivity analyses.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Ranibizumab and bevacizumab have similar efficacy. Discontinuing treatment and restarting when required results in slightly worse efficacy. Safety was worse with discontinuous treatment, although new GA developed more often with continuous treatment. Ranibizumab is not cost-effective, although it remains uncertain whether or not continuous bevacizumab is cost-effective compared with discontinuous bevacizumab at \u00a320,000 per QALY threshold. Future studies should focus on the ocular safety of the two drugs, further optimisation of treatment regimens and criteria for stopping treatment.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n Current Controlled Trials ISRCTN92166560.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n \n This project was funded by the NIHR Health Technology Assessment programme and will be published in full in\n Health Technology Assessment<\/jats:italic>\n ; Vol. 19, No. 78. See the NIHR Journals Library website for further project information.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/hta19780","type":"journal-article","created":{"date-parts":[[2015,10,8]],"date-time":"2015-10-08T07:08:23Z","timestamp":1444288103000},"page":"1-298","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":72,"title":["A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN)"],"prefix":"10.3310","volume":"19","clinical-trial-number":[{"clinical-trial-number":"isrctn92166560","registry":"10.18810\/isrctn","type":"results"}],"author":[{"given":"Usha","family":"Chakravarthy","sequence":"first","affiliation":[{"name":"Centre for Experimental Medicine, Institute of Clinical Science, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon P","family":"Harding","sequence":"additional","affiliation":[{"name":"Department of Eye and Vision Science, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris A","family":"Rogers","sequence":"additional","affiliation":[{"name":"Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Downes","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals NHS Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J","family":"Lotery","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen A","family":"Dakin","sequence":"additional","affiliation":[{"name":"Health Economic Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Culliford","sequence":"additional","affiliation":[{"name":"Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren J","family":"Scott","sequence":"additional","affiliation":[{"name":"Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L","family":"Nash","sequence":"additional","affiliation":[{"name":"Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi","family":"Taylor","sequence":"additional","affiliation":[{"name":"Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Muldrew","sequence":"additional","affiliation":[{"name":"Centre for Experimental Medicine, Institute of Clinical Science, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayashree","family":"Sahni","sequence":"additional","affiliation":[{"name":"Department of Eye and Vision Science, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Wordsworth","sequence":"additional","affiliation":[{"name":"Health Economic Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Raftery","sequence":"additional","affiliation":[{"name":"Wessex Institute, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tunde","family":"Peto","sequence":"additional","affiliation":[{"name":"National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnaby C","family":"Reeves","sequence":"additional","affiliation":[{"name":"Clinical Trials and Evaluation Unit, School of Clinical Sciences, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the IVAN Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2015,10]]},"reference":[{"key":"key20151008120409806_ref1-bib1","volume-title":"Photodynamic Therapy for Age-related Macular Degeneration","author":"National Institute for Health and Care Excellence (NICE)","year":"2003"},{"key":"key20151008120409806_ref1-bib2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1076\/opep.10.3.149.15080","article-title":"Measurement and analysis of visual acuity in multicenter randomized clinical trials in the United States: findings from a survey","volume":"10","author":"Dong","year":"2003","journal-title":"Ophthalmic Epidemiol"},{"key":"key20151008120409806_ref1-bib3","first-page":"198","article-title":"Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study G. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2","volume":"119","author":"Bressler","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"key20151008120409806_ref1-bib4","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N Engl J Med"},{"key":"key20151008120409806_ref1-bib5","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/archopht.117.10.1329","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials \u2013 TAP report","volume":"117","author":"Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"key20151008120409806_ref1-bib6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"key20151008120409806_ref1-bib7","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"key20151008120409806_ref1-bib8","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"key20151008120409806_ref1-bib9","first-page":"361","article-title":"Ranibizumab: Phase III clinical trial results","volume":"19","author":"Rosenfeld","year":"2006","journal-title":"Ophthalmol Clin North Am"},{"key":"key20151008120409806_ref1-bib10","volume-title":"Variable Dosing of Ranibizumab Investigated for Treatment of Neovascular AMD Ophthalmology Times","author":"Anon"},{"key":"key20151008120409806_ref1-bib11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/00006982-200604000-00001","article-title":"Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"key20151008120409806_ref1-bib12","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ophtha.2006.05.070","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study","volume":"113","author":"Moshfeghi","year":"2006","journal-title":"Ophthalmology"},{"key":"key20151008120409806_ref1-bib13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"key20151008120409806_ref1-bib14","doi-asserted-by":"publisher","first-page":"12439","DOI":"10.1523\/JNEUROSCI.0434-06.2006","article-title":"Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1\/2 and Akt pathways","volume":"26","author":"Kilic","year":"2006","journal-title":"J Neurosci"},{"key":"key20151008120409806_ref1-bib15","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1167\/iovs.05-1229","article-title":"VEGF expression and receptor activation in the choroid during development and in the adult","volume":"47","author":"Saint-Geniez","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20151008120409806_ref1-bib16","first-page":"1508","article-title":"Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration","volume":"113","author":"Chakravarthy","year":"2006","journal-title":"Ophthalmology"},{"key":"key20151008120409806_ref1-bib17","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1098\/rstb.2005.1693","article-title":"Pharmacogenetics in drug regulation: promise, potential and pitfalls","volume":"360","author":"Shah","year":"2005","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"key20151008120409806_ref1-bib18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2217\/14622416.8.1.49","article-title":"Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy","volume":"8","author":"Pasqualetti","year":"2007","journal-title":"Pharmacogenomics"},{"key":"key20151008120409806_ref1-bib19","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/ng1873","article-title":"Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration","volume":"38","author":"Maller","year":"2006","journal-title":"Nat Genet"},{"key":"key20151008120409806_ref1-bib20","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/ng1890","article-title":"A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration","volume":"38","author":"Hughes","year":"2006","journal-title":"Nat Genet"},{"key":"key20151008120409806_ref1-bib21","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1126\/science.1133807","article-title":"HTRA1 promoter polymorphism in wet age-related macular degeneration","volume":"314","author":"Dewan","year":"2006","journal-title":"Science"},{"key":"key20151008120409806_ref1-bib22","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"key20151008120409806_ref1-bib23","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"CATT Research Group","year":"2011","journal-title":"N Engl J Med"},{"key":"key20151008120409806_ref1-bib24","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1167\/iovs.04-0601","article-title":"Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration","volume":"46","author":"Gaudreault","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20151008120409806_ref1-bib25","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1345\/aph.1H316","article-title":"Bevacizumab for neovascular ocular diseases","volume":"41","author":"Lynch","year":"2007","journal-title":"Ann Pharmacother"},{"key":"key20151008120409806_ref1-bib26","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"The IVAN Study Investigators","year":"2012","journal-title":"Ophthalmology"},{"key":"key20151008120409806_ref1-bib27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0002-9394(82)90197-0","article-title":"New visual acuity charts for clinical research","volume":"94","author":"Ferris","year":"1982","journal-title":"Am J Ophthalmol"},{"key":"key20151008120409806_ref1-bib28","first-page":"187","article-title":"The design of a new letter chart for measuring contrast sensitivity","volume":"2","author":"Pelli","year":"1988","journal-title":"Clin Vis Sci"},{"key":"key20151008120409806_ref1-bib29","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/00006324-198006000-00011","article-title":"The design and use of a new near-vision chart","volume":"57","author":"Bailey","year":"1980","journal-title":"Am J Optom Physiol Opt"},{"key":"key20151008120409806_ref1-bib30","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/archopht.120.8.1029","article-title":"Visual outcomes in the subfoveal radiotherapy study: a randomized controlled trial of teletherapy for age-related macular degeneration","volume":"120","author":"Hart","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"key20151008120409806_ref1-bib31","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1136\/bjo.84.3.244","article-title":"Macular degeneration: do conventional measurements of impaired visual function equate with visual disability?","volume":"84","author":"McClure","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"key20151008120409806_ref1-bib32","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"A new facility for the measurement of health-related quality-of-life","volume":"16","author":"Williams","year":"1990","journal-title":"Health Policy"},{"key":"key20151008120409806_ref1-bib33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/00005650-200202000-00006","article-title":"Multiattribute and single-attribute utility functions for the health utilities index mark 3 system","volume":"40","author":"Feeny","year":"2002","journal-title":"Med Care"},{"key":"key20151008120409806_ref1-bib34","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1023\/B:QURE.0000031348.51292.4a","article-title":"Design of an individualised measure of the impact of macular disease on quality of life (the MacDQoL)","volume":"13","author":"Mitchell","year":"2004","journal-title":"Qual Life Res"},{"key":"key20151008120409806_ref1-bib35","first-page":"A1150","article-title":"Design of a measure of satisfaction with treatment for macular degeneration (MacTSQ)","volume":"A120","author":"Mitchell","year":"2007","journal-title":"Qual Life Res"},{"key":"key20151008120409806_ref1-bib36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy \u2013 I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","author":"Antiplatelet Trialists\u2019 Collaboration","year":"1994","journal-title":"BMJ"},{"key":"key20151008120409806_ref1-bib37","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988","edition":"2nd edn."},{"key":"key20151008120409806_ref1-bib38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1475-1313.1993.tb00421.x","article-title":"Reliability of high- and low-contrast letter charts","volume":"13","author":"Reeves","year":"1993","journal-title":"Ophthalmic Physiol Opt"},{"key":"key20151008120409806_ref1-bib39","volume-title":"Fluctuating Levels of Circulating VEGF in a Subset of Patients as Part of the Multicentre IVAN Study","author":"The Association for Research in Vision and Ophthalmology (ARVO) Annual Conference 2011","year":"2011"},{"key":"key20151008120409806_ref1-bib40","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1001\/jama.2012.87802","article-title":"Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement","volume":"308","author":"Piaggio","year":"2012","journal-title":"JAMA"},{"key":"key20151008120409806_ref1-bib41","volume-title":"ICH Harmonised Tripartite Guideline Topic E9: Statistical Principles for Clinical Trials","author":"International Conference on Harmonisation (ICH)"},{"key":"key20151008120409806_ref1-bib42","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1016\/j.ophtha.2013.06.020","article-title":"Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial","volume":"120","author":"Kodjikian","year":"2013","journal-title":"Ophthalmology"},{"key":"key20151008120409806_ref1-bib43","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1136\/bjophthalmol-2012-302391","article-title":"A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration","volume":"97","author":"Krebs","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"key20151008120409806_ref1-bib44","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1038\/eye.2010.147","article-title":"Bevacizumab vs. ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial","volume":"24","author":"Subramanian","year":"2010","journal-title":"Eye"},{"key":"key20151008120409806_ref1-bib45","volume-title":"Guide to the Methods of Technology Appraisal 2013","author":"National Institute for Health and Care Excellence (NICE)","year":"2013"},{"key":"key20151008120409806_ref1-bib46","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/sim.4780080204","article-title":"Factorial designs in clinical trials: the effects of non-compliance and subadditivity","volume":"8","author":"Brittain","year":"1989","journal-title":"Stat Med"},{"key":"key20151008120409806_ref1-bib47","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/0197-2456(85)90010-8","article-title":"Factorial designs for randomized clinical trials","volume":"69","author":"Byar","year":"1985","journal-title":"Cancer Treat Res"},{"key":"key20151008120409806_ref1-bib48","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/j.1444-0938.2008.00305.x","article-title":"Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice","volume":"91","author":"Van Wijngaarden","year":"2008","journal-title":"Clin Exp Optom"},{"key":"key20151008120409806_ref1-bib49","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1600-0420.2006.00869.x","article-title":"Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis?","volume":"85","author":"La Cour","year":"2007","journal-title":"Acta Ophthalmol Scand"},{"key":"key20151008120409806_ref1-bib50","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000316695","article-title":"Retinal and ocular toxicity in ocular application of drugs and chemicals \u2013 part II: retinal toxicity of current and new drugs","volume":"44","author":"Penha","year":"2010","journal-title":"Ophthalmic Res"},{"key":"key20151008120409806_ref1-bib51","volume-title":"British National Formulary","author":"British Medical Association and Royal Pharmaceutical Society of Great Britain","year":"2011"},{"key":"key20151008120409806_ref1-bib52","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1001\/jama.289.19.2545","article-title":"Analysis and reporting of factorial trials: a systematic review","volume":"289","author":"McAlister","year":"2003","journal-title":"JAMA"},{"key":"key20151008120409806_ref1-bib53","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2005","edition":"3rd edn."},{"key":"key20151008120409806_ref1-bib54","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/hec.1812","article-title":"Cost-minimisation analysis versus cost-effectiveness analysis, revisited","volume":"22","author":"Dakin","year":"2013","journal-title":"Health Econ"},{"key":"key20151008120409806_ref1-bib55","volume-title":"Time Trade-off User Manual: Props and Self-completion Methods","author":"Gudex","year":"1994"},{"key":"key20151008120409806_ref1-bib56","volume-title":"The Measurement and Valuation of Health: A Chronicle","author":"Williams","year":"1995"},{"key":"key20151008120409806_ref1-bib57","volume-title":"Social Value Judgements: Principles for the Development of NICE Guidance","author":"National Institute for Health and Care Excellence (NICE)","year":"2008","edition":"2nd edn."},{"key":"key20151008120409806_ref1-bib58","volume-title":"Applied Methods of Cost-Effectiveness Analysis in Health Care","author":"Gray","year":"2011"},{"key":"key20151008120409806_ref1-bib59","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/hec.635","article-title":"Representing uncertainty: the role of cost-effectiveness acceptability curves","volume":"10","author":"Fenwick","year":"2001","journal-title":"Health Econ"},{"key":"key20151008120409806_ref1-bib60","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"key20151008120409806_ref1-bib61","volume-title":"Measuring Self-Reported Population Health: An International Perspective Based on EQ-5D","author":"Szende","year":"2004"},{"key":"key20151008120409806_ref1-bib62","doi-asserted-by":"publisher","first-page":"490","DOI":"10.2165\/00019053-199507060-00004","article-title":"Multi-attribute health status classification systems. Health Utilities Index","volume":"7","author":"Feeny","year":"1995","journal-title":"PharmacoEconomics"},{"key":"key20151008120409806_ref1-bib63","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2165\/00019053-199507060-00005","article-title":"Multi-attribute preference functions. Health Utilities Index","volume":"7","author":"Torrance","year":"1995","journal-title":"PharmacoEconomics"},{"key":"key20151008120409806_ref1-bib64","volume-title":"A Social Tariff for Euroqol: Results from a UK General Population Survey","author":"Dolan","year":"1995"},{"key":"key20151008120409806_ref1-bib65","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1017\/S0266462306051051","article-title":"Use of quality-adjusted life years for the estimation of effectiveness of health care: a systematic literature review","volume":"22","author":"Rasanen","year":"2006","journal-title":"Int J Technol Assess Health Care"},{"key":"key20151008120409806_ref1-bib66","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1167\/iovs.05-0072","article-title":"The impact of age-related macular degeneration on health status utility values","volume":"46","author":"Espallargues","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key20151008120409806_ref1-bib67","volume-title":"A Review of Generic Preference-based Measures of Health-related Quality of Life in Visual Disorders","author":"Tosh","year":"2011"},{"key":"key20151008120409806_ref1-bib68","first-page":"239","volume-title":"Quality of Life and Pharmacoeconomics in Clinical Trials","author":"Feeny","year":"1996","edition":"2nd edn."},{"key":"key20151008120409806_ref1-bib69","volume-title":"Multiplicative Multi-Attribute Utility Function for the Health Utilities Index Mark 3 (HUI3) System: A Technical Report","author":"Furlong","year":"1998"},{"key":"key20151008120409806_ref1-bib70","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jval.2010.10.004","article-title":"Imputing QALYs from single time point health state descriptions on the EQ-5D and the SF-6D: a comparison of methods for hepatitis a patients","volume":"14","author":"Luyten","year":"2011","journal-title":"Value Health"},{"key":"key20151008120409806_ref1-bib71","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2165\/00019053-200523060-00008","article-title":"Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease","volume":"23","author":"Spencer","year":"2005","journal-title":"PharmacoEconomics"},{"key":"key20151008120409806_ref1-bib72","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1017\/S0266462300010229","article-title":"Economic evaluation alongside multinational clinical trials. Study considerations for GUSTO IIb","volume":"13","author":"Jonsson","year":"1997","journal-title":"Int J Technol Assess Health Care"},{"key":"key20151008120409806_ref1-bib73","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","article-title":"Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party","volume":"313","author":"Drummond","year":"1996","journal-title":"BMJ"},{"key":"key20151008120409806_ref1-bib74","volume-title":"Ranibizumab and Pegaptanib for the Treatment of Age-Related Macular Degeneration TA155","author":"National Institute for Health and Care Excellence (NICE)","year":"2012"},{"key":"key20151008120409806_ref1-bib75","volume-title":"National Schedule of Reference Costs 2010\u201311 for NHS Trusts and PCTs Combined","author":"Department of Health (DH)","year":"2011"},{"key":"key20151008120409806_ref1-bib76","volume-title":"PbR Operational Guidance and Tariffs: 2011\u201312 Tariff Information Spreadsheet","author":"Department of Health (DH)","year":"2011"},{"key":"key20151008120409806_ref1-bib77","volume-title":"Unit Costs of Health and Social Care 2011","author":"Curtis","year":"2011"},{"key":"key20151008120409806_ref1-bib78","volume-title":"NHS Staff Earnings January \u2013 March 2011","author":"Health and Social Care Information Centre (HSCIC)","year":"2011"},{"key":"key20151008120409806_ref1-bib79","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1177\/0962280206074464","article-title":"Evaluation of software for multiple imputation of semi-continuous data","volume":"16","author":"Yu","year":"2007","journal-title":"Stat Methods Med Res"},{"key":"key20151008120409806_ref1-bib80","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/hec.766","article-title":"Missing .\u2009.\u2009. presumed at random: cost-analysis of incomplete data","volume":"12","author":"Briggs","year":"2003","journal-title":"Health Econ"},{"key":"key20151008120409806_ref1-bib81","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"key20151008120409806_ref1-bib82","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1536867X0400400301","article-title":"Multiple imputation of missing values","volume":"4","author":"Royston","year":"2004","journal-title":"STATA J"},{"key":"key20151008120409806_ref1-bib83","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1177\/1536867X0500500404","article-title":"Multiple imputation of missing values: update of ice","volume":"5","author":"Royston","year":"2005","journal-title":"STATA J"},{"key":"key20151008120409806_ref1-bib84","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/1536867X0800700401","article-title":"Multiple imputation of missing values: further update of ice, with an emphasis on interval censoring","volume":"7","author":"Royston","year":"2007","journal-title":"STATA J"},{"key":"key20151008120409806_ref1-bib85","first-page":"15","article-title":"Treatment of age-related macular degeneration with intravitreous injections of bevacizumab (Avastin): short-term results","author":"De Clercq","journal-title":"Bull Soc Belge Ophthalmol"},{"key":"key20151008120409806_ref1-bib86","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/00005650-199803000-00019","article-title":"On estimating costs for economic evaluation in failure time studies","volume":"36","author":"Hallstrom","year":"1998","journal-title":"Med Care"},{"key":"key20151008120409806_ref1-bib87","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2307\/2533947","article-title":"Estimating medical costs from incomplete follow-up data","volume":"53","author":"Lin","year":"1997","journal-title":"Biometrics"},{"key":"key20151008120409806_ref1-bib88","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2288-3-26","article-title":"Design, analysis and presentation of factorial randomised controlled trials","volume":"3","author":"Montgomery","year":"2003","journal-title":"BMC Med Res Methodol"},{"key":"key20151008120409806_ref1-bib89","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/hec.944","article-title":"Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility","volume":"14","author":"Manca","year":"2005","journal-title":"Health Econ"},{"key":"key20151008120409806_ref1-bib90","volume-title":"The Green Book: Appraisal and Evaluation in Central Government","author":"HM Treasury","year":"2003"},{"key":"key20151008120409806_ref1-bib91","volume-title":"Ranibizumab and Pegaptanib for the Treatment of Age-related Macular Degeneration","author":"National Institute for Health and Care Excellence (NICE)","year":"2008"},{"issue":"6","key":"key20151008120409806_ref1-bib92","doi-asserted-by":"publisher","DOI":"10.3310\/hta16060","article-title":"Verteporfin photodynamic therapy for neovascular age-related macular degeneration: cohort study for the UK","volume":"16","author":"Reeves","year":"2012","journal-title":"Health Technol Assess"},{"key":"key20151008120409806_ref1-bib93","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"key20151008120409806_ref1-bib94","volume-title":"UK Population Norms for EQ-5D","author":"Kind","year":"1999"},{"key":"key20151008120409806_ref1-bib95","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/hec.584","article-title":"The death of cost-minimization analysis?","volume":"10","author":"Briggs","year":"2001","journal-title":"Health Econ"},{"key":"key20151008120409806_ref1-bib96","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"key20151008120409806_ref1-bib97","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.amjcard.2008.02.027","article-title":"The safety of niacin in the US Food and Drug Administration adverse event reporting database","volume":"101","author":"Alsheikh-Ali","year":"2008","journal-title":"Am J Cardiol"},{"key":"key20151008120409806_ref1-bib98","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1136\/bjo.2007.116616","article-title":"Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness","volume":"91","author":"Raftery","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"key20151008120409806_ref1-bib99","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/eye.2009.85","article-title":"Should avastin be used to treat age-related macular degeneration in the NHS? \u2013 Yes","volume":"23","author":"Raftery","year":"2009","journal-title":"Eye"},{"key":"key20151008120409806_ref1-bib100","volume-title":"Ranibizumab and Pegaptanib for the Treatment of Age-related Macular Degeneration TA155: Costing Template and Report","author":"National Institute for Health and Care Excellence (NICE)","year":"2008"},{"key":"key20151008120409806_ref1-bib101","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1001\/archopht.130.1.124","article-title":"Risks of adverse events with therapies for age-related macular degeneration: a response","volume":"130","author":"Williams","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"key20151008120409806_ref1-bib102","doi-asserted-by":"publisher","first-page":"e42701","DOI":"10.1371\/journal.pone.0042701","article-title":"A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard","volume":"7","author":"Schmucker","year":"2012","journal-title":"PLOS ONE"},{"key":"key20151008120409806_ref1-bib103","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/ICU.0b013e3283386783","article-title":"Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review","volume":"21","author":"Schmucker","year":"2010","journal-title":"Curr Opin Ophthalmol"},{"key":"key20151008120409806_ref1-bib104","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1001\/archophthalmol.2010.223","article-title":"Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration","volume":"128","author":"Curtis","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"key20151008120409806_ref1-bib105","doi-asserted-by":"publisher","first-page":"e4203","DOI":"10.1136\/bmj.e4203","article-title":"Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study","volume":"345","author":"Campbell","year":"2012","journal-title":"BMJ"},{"key":"key20151008120409806_ref1-bib106","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/IAE.0b013e318276e07b","article-title":"Myocardial infarction after intravitreal vascular endothelial growth factor inhibitors: a whole population study","volume":"33","author":"Kemp","year":"2013","journal-title":"Retina"},{"key":"key20151008120409806_ref1-bib107","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1001\/archopht.124.11.1532","article-title":"Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study","volume":"124","author":"Heier","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"key20151008120409806_ref1-bib108","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"key20151008120409806_ref1-bib109","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ajo.2010.04.011","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2","volume":"150","author":"Abraham","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"key20151008120409806_ref1-bib110","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/archopht.118.1.47","article-title":"Utility values and age-related macular degeneration","volume":"118","author":"Brown","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"key20151008120409806_ref1-bib111","first-page":"473","article-title":"Vision and quality-of-life","volume":"97","author":"Brown","year":"1999","journal-title":"Trans Am Ophthalmol Soc"},{"key":"key20151008120409806_ref1-bib112","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","article-title":"The estimation of a preference-based measure of health from the SF-36","volume":"21","author":"Brazier","year":"2002","journal-title":"J Health Econ"},{"key":"key20151008120409806_ref1-bib113","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ophtha.2012.07.026","article-title":"The SECURE study: long-term safety of ranibizumab 0.5\u2009mg in neovascular age-related macular degeneration","volume":"120","author":"Silva","year":"2013","journal-title":"Ophthalmology"},{"key":"key20151008120409806_ref1-bib114","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.ophtha.2011.12.016","article-title":"HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration","volume":"119","author":"Singer","year":"2012","journal-title":"Ophthalmology"},{"key":"key20151008120409806_ref1-bib115","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ophtha.2012.07.068","article-title":"Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET)","volume":"120","author":"Dugel","year":"2013","journal-title":"Ophthalmology"},{"key":"key20151008120409806_ref1-bib116","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/OPTH.S16444","article-title":"Radiation therapy for neovascular age-related macular degeneration","volume":"5","author":"Petrarca","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"key20151008120409806_ref1-bib117","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1","volume":"145","author":"Regillo","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"key20151008120409806_ref1-bib118","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","article-title":"Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study","volume":"118","author":"Holz","year":"2011","journal-title":"Ophthalmology"},{"key":"key20151008120409806_ref1-bib119","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ophtha.2010.09.004","article-title":"Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study","volume":"118","author":"Schmidt-Erfurth","year":"2011","journal-title":"Ophthalmology"},{"key":"key20151008120409806_ref1-bib120","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/bmj.39129.442164.55","article-title":"Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study","volume":"334","author":"Griffin","year":"2007","journal-title":"BMJ"},{"key":"key20151008120409806_ref1-bib121","volume-title":"Patient Reported Outcome Measures (PROMs) in Elective Surgery: Report to the Department of Health","author":"Browne","year":"2007"},{"issue":"9","key":"key20151008120409806_ref1-bib122","doi-asserted-by":"publisher","DOI":"10.3310\/hta18090","article-title":"Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey","volume":"18","author":"Longworth","year":"2014","journal-title":"Health Technol Assess"},{"key":"key20151008120409806_ref1-bib123","volume-title":"CHMP Assessment Report: Eylea aflibercept","author":"European Medicines Agency Committee for Medicinal Products for Human Use","year":"2012"},{"key":"key20151008120409806_ref1-bib124","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/BF00435981","article-title":"Comparison of two methods of calculating quality-adjusted life years","volume":"5","author":"Ganiats","year":"1996","journal-title":"Qual Life Res"},{"issue":"10","key":"key20151008120409806_ref1-bib125","doi-asserted-by":"crossref","DOI":"10.3310\/hta3100","article-title":"Methods for the analysis of quality-of-life and survival data in health technology assessment","volume":"3","author":"Billingham","year":"1999","journal-title":"Health Technol Assess"},{"key":"key20151008120409806_ref1-bib126","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jval.2011.08.002","article-title":"A review of generic preference-based measures of health-related quality of life in visual disorders","volume":"15","author":"Tosh","year":"2012","journal-title":"Value Health"},{"key":"key20151008120409806_ref1-bib127","volume-title":"Unit Costs of Health and Social Care 2010","author":"Curtis","year":"2010"},{"key":"key20151008120409806_ref1-bib128","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/heapro\/7.4.249","article-title":"Community pharmacists and health promotion: a study of consultations between pharmacists and clients","volume":"7","author":"Smith","year":"1992","journal-title":"Health Promot Int"},{"key":"key20151008120409806_ref1-bib129","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jhealeco.2003.06.006","article-title":"On estimators of medical costs with censored data","volume":"23","author":"O\u2019Hagan","year":"2004","journal-title":"J Health Econ"},{"key":"key20151008120409806_ref1-bib130","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/oxfordjournals.eurheartj.a060552","article-title":"Factorial trials in cardiology: pros and cons","volume":"15","author":"Lubsen","year":"1994","journal-title":"Eur Heart J"},{"key":"key20151008120409806_ref1-bib131","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0167-6296(98)00039-3","article-title":"The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies","volume":"18","author":"Claxton","year":"1999","journal-title":"J Health Econ"},{"key":"key20151008120409806_ref1-bib132","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W","article-title":"Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation","volume":"6","author":"Briggs","year":"1997","journal-title":"Health Econ"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta19780\/hta19780.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002278","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta19780\/hta19780.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002764","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T13:12:04Z","timestamp":1718111524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta19780\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":132,"journal-issue":{"issue":"78","published-online":{"date-parts":[[2015,10]]}},"alternative-id":["10.3310\/hta19780"],"URL":"https:\/\/doi.org\/10.3310\/hta19780","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}